

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Otilimab,Methotrexate,Sulfasalazine
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GSK3196165 (otilimab) is an investigational human monoclonal antibody directed against GM-CSF (granulocyte-macrophage colony-stimulating factor) that is developed by GSK for the treatment of rheumatoid arthritis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Otilimab,Methotrexate,Sulfasalazine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Otilimab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab
Details : Otilimab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : Otilimab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Otilimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pre-planned efficacy analysis by age in patients 70 years and older showed that 65.1% of patients were alive and free of respiratory failure 28 days after treatment with otilimab plus standard of care, compared to 45.9% of patients who received the stand...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 25, 2021
Lead Product(s) : Otilimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Otilimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK begins US test of experimental drug for pneumonia caused by COVID-19
Details : GlaxoSmithKline has started a trial in the United States to test an experimental rheumatoid arthritis drug on patients suffering from pneumonia caused by COVID-19.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 09, 2020
Lead Product(s) : Otilimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Otilimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK to Test Experimental Drug to Treat Pneumonia from COVID-19
Details : GSK found that otilimab could possibly ease the devastating effect of the virus on the lungs but not suppress it directly, a company spokesman said.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 07, 2020
Lead Product(s) : Otilimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Otilimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
Details : Otilimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Severe Acute Respiratory Syndrome.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 06, 2020
Lead Product(s) : Otilimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Otilimab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
Details : Otilimab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 03, 2020
Lead Product(s) : Otilimab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Otilimab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Otilimab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 22, 2019
Lead Product(s) : Otilimab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Otilimab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Otilimab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 10, 2019
Lead Product(s) : Otilimab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Otilimab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Otilimab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 03, 2019
Lead Product(s) : Otilimab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
